"Pyridostigmine Bromide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.
| Descriptor ID |
D011729
|
| MeSH Number(s) |
D03.383.725.762.740
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridostigmine Bromide".
Below are MeSH descriptors whose meaning is more specific than "Pyridostigmine Bromide".
This graph shows the total number of publications written about "Pyridostigmine Bromide" by people in this website by year, and whether "Pyridostigmine Bromide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridostigmine Bromide" by people in Profiles.
-
Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental? BMJ Case Rep. 2021 Jul 21; 14(7).
-
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol. BMC Infect Dis. 2020 Oct 16; 20(1):765.
-
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis. J Clin Neuromuscul Dis. 2020 Sep; 22(1):60-62.
-
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report. Clin Neurol Neurosurg. 2020 09; 196:106045.
-
Myasthenia gravis unmasked by imatinib. Br J Haematol. 2019 02; 184(3):321.
-
Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation. 2018 02 27; 137(9):910-924.
-
[Cardiac effects of GH]. Minerva Endocrinol. 1993 Sep; 18(3 Suppl 1):69-75.